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Abstract 
Introduction: Depression is a quite common comorbidity in patients with rheumatoid arthritis (RA) and is thought 
to influence its severity. This study aims to estimate, in a large cohort of Italian patients with RA, the prevalence of 
depression and to investigate the clinical correlates of depression in terms of disease activity and disability.
Methods: This is a cross-sectional study enrolling 490 outpatients with RA (80% female, mean age 59.5). The Hospital 
Anxiety and Depression Scale (HADS) was used to assess the presence of depression with a cut-off of 11. We collected 
data about disease activity and disability with DAS28, TJC-68, PhGA, PGA, VAS, DAS28, SDAI, CDAI and HAQ.
Results: Prevalence of depression was 14.3% (95% CI: 11-17%). Depressed patients, when compared with not 
depressed ones, were found to have higher scores for TJC-68 (p = 0.011), PhGA (p = 0.001), PGA (p = 0.001), VAS 
(p = 0.001), DAS28 (p = 0.007), SDAI (p = 0.001), CDAI (p = 0.001) and HAQ (p = 0.001). Out of the 70 depressed 
patients, 30 subjects, already known to be depressed in the past, were still depressed at the time of the assessment, 
with only 11 (15.7%) under antidepressants. A multivariate analysis showed that male sex, higher PGA score, use of 
antidepressants and higher HAQ score were significantly associated with an increased risk of depression.
Conclusions: Our study shows that depression is common in RA and may affect its activity mainly via an alteration 
in the perception of the disease. Although its important implications, depression is still under-diagnosed and its man-
agement is inadequate.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease with a prevalence of 0.5–1% in Europe, with 
the lower values in southern countries [1]. It primar-
ily involves peripheral joints, damaging cartilages and 
bones, and leads progressively to disability. RA shows 
also systemic manifestations and it has been associated to 
systemic comorbidities, as depressive and anxiety disor-
ders [2].
In patients with RA, the prevalence of depression 
ranges between 14.8 and 22.5%, which is two to three 
times higher than in the general population [3], reach-
ing a 47% lifetime risk [4, 5]. In addition, about 39% of 
patients affected by RA have also sub-threshold depres-
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often in females with RA as compared to males suffering 
from RA [6].
The presence of depression has been associated with 
increased pain perception [4], increased level of physical 
disability [7], enhanced health care costs [6], and greater 
mortality [4]. Notably, it has been demonstrated a sig-
nificant association between persistent depression and 
high continuous disease activity, measured by the Clini-
cal Disease Activity Index (CDAI) [8]. Notably, most of 
the activity scores commonly used in rheumatology are 
based also on subjective measures that may be affected 
by the psychological status [9] and may further influence 
the assessment of disease activity.
Finally, depression was found to be a strong negative 
predictor of remission [10], thus should be evaluated 
in every patient in order to increase the probability of a 
good disease control.
Since there is a possibly bidirectional relationship 
between the severity of both rheumatic disease and 
depressive disorders, it is fundamental to study the clini-
cal correlates of depression in RA patients in order to 
improve the clinical outcome of RA.
The present study aims (1) to estimate, in a large sam-
ple of Italian patients affected by Rheumatoid Arthritis, 
the prevalence of depressive disorders; and (2) to inves-
tigate the clinical correlates of depression in terms of RA 
disease activity and disability. Specifically, we hypoth-
esized that RA individuals affected by depression were 
characterized by higher levels of RA disease activity 
and disability when compared to non-depressed ones. 
The present study offers the opportunity to increase our 
knowledge on the comorbidity by investigating depres-
sion and its clinical correlates, as part of the routine 
clinical monitoring, in a large real life RA sample from a 
real-world outpatient setting. Studying the clinical corre-
lates of depression in RA is a relevant issue in order to 
define appropriate screening and treatment programs to 
prevent worse outcome for both depression and RA.
Material and methods
This is an observational, cross-sectional study examin-
ing the clinical correlates of depressive disorders in a 
cohort of patients affected by Rheumatoid Arthritis on 
DMARDs treatment for at least one year. Individuals fol-
lowed at the Unit of Rheumatology, University Hospital 
of Verona, Italy, in the period between March 2016 and 
February 2017 were enrolled during a routine outpatient 
visit. The inclusion criteria were: (1) age ≥ 18  years; (2) 
RA diagnosis according to the American College of Rheu-
matology (ACR)/ European League Against Rheumatism 
(EULAR) 2010 [11]. Individuals with fibromyalgia, con-
nective tissue diseases (LES, Sjogren, sclerodermas, der-
matomyositis, polymyositis), vasculitis, gout, infective 
arthritis, rheumatic polymyalgia or other severe systemic 
diseases were excluded.
A comprehensive set of standardized instruments 
was used to collect socio-demographic and clinical 
information.
Specifically, RA-related characteristics including dis-
ease duration, 28 tender/swollen joints count (TJC 28/
SJC 28) [12], 68 tender/swollen joints count (TJC 68/
SJC 68), Visual Analogue Scale (VAS, 0–100  mm) for 
joint pain, Physician Global Assessment (PhGA, 0–10) 
and Patient Global Assessment (PGA, 0–10), were col-
lected. RA disease activity and disability were assessed 
with 28-joints Disease Activity Score (DAS28) [1], Sim-
plified Disease Activity Index (SDAI) [1], Clinical Dis-
ease Activity Index (CDAI) [1] and Health Assessment 
Questionnaires (HAQ) [13]. Patients were assessed for 
the presence of any comorbidity and for smoking. Data 
about current rheumatic medications, antidepressants or 
benzodiazepines were recorded. Body Mass Index (BMI, 
kg/m2) was calculated as following: weight was meas-
ured without shoes, and in light indoor clothes, using a 
balance beam scale; height was measured without shoes 
using a fixed stadiometer.
Blood samples were collected to detect the presence of 
anti-citrullinated protein antibody (ACPA) and/or rheu-
matoid factor (RF), erythrocyte sedimentation rate (ESR, 
mm/hour), C-reactive protein (CRP; mg/L), vitamin D 
level (25-OH-D3, nmol/L).
Depressive and anxious symptomatology was assessed 
using the Hospital Anxiety and Depression Scale (HADS) 
[8]. The HADS is a self-administered instrument validated 
in a hospital setting and developed for evaluating depres-
sion in somatic primary or secondary care [9]. It is com-
posed by two subscales, one for depression (HADS-D) and 
one for anxiety (HADS-A), each constituted by seven items. 
Every item is scored from 0 to 3, and higher scores indicate 
more severe symptoms. Total sum score ranges from 0 to 
21 for HADS-D. For the present study, we decided to use 
only the HADS-D with a cut-off of 11, allowing us to iden-
tify with greater specificity depressed subjects.
The investigation was carried out in accordance with 
the latest version of the Declaration of Helsinki [14].
Statistical analyses
Descriptives were given for all variables. Compari-
sons between depressed patients (HADS-D score ≥ 11) 
and not depressed patients (HADS-D score < 11) were 
assessed by Chi-square tests for categorical variables and 
t-tests (2 independent groups) for continuous variables. 
Each socio-demographic and clinical variable which 
resulted significantly different in the two groups was 
entered into a univariable linear regression model with 
HADS-D score as the dependent variable. Subsequently, 
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only those variables associated at p < 0.10 entered into 
a series of multivariable hierarchical linear regression 
models (model 1: demographics; model 2: plus RA-
related variables; model 3: plus RA therapy; model 4: plus 
psychotropic therapy; model 5: plus RA disease activity 
and disability indices). The R-square change at each step 
was used to determine the variance explained by each set 
of variables. Collinearity among the independent vari-
ables was explored by calculating the individual variance 
inflation factors. In the final model, these values ranged 
between 1.10 and 3.29, thus indicating the absence of 
multicollinearity. All tests were 2-tailed. Statistical analy-
ses were performed using SPSS 22 for Windows.
Results
Prevalence of depression and its association 
with socio‑demographic characteristics
We assessed 490 patients with RA (80% female, with 
mean age of about 60 years). We found that the prev-
alence of depression was 14.3% (95% CI: 11–17%). 
Indeed, out of the 490 participants, 70 patients 
scored ≥ 11 in HADS-D questionnaire (Table  1). 
Depression was more frequent in females and in 
unemployed patients (p = 0.001 and p = 0.034, respec-
tively). No other socio-demographic characteristics 
were associated with depression.
The association between depression and clinical 
characteristics
We found that out of 70 depressed patients, 30 (42.9%) 
reported a personal history of depression. Moreo-
ver, patients with depression, when compared to 
non-depressed ones, have higher TJC68 (p = 0.011), 
PhGA (p < 0.011), PGA (p < 0.011) and VAS (p < 0.011) 
(Table  2). There were no differences between the two 
groups in terms of duration of illness, RF and/or ACPA 
seropositive form, number of erosions, family history of 
rheumatic disease, TJC28, SJC28, SJC66 and biological 
characteristics.
Most patients (90.8%) presented at least one comor-
bidity, with the cardiovascular the most represented 
one (56.1%) (Table  3). Regarding comorbidity, there 
were no differences between the two groups.
By considering medications (Table  4), almost half 
of the cohort (49.4%) used steroids, with a difference 
between depressed (60.0%) and not depressed (47.6%) 
patients (p = 0.050). One hundred and four patients 
(21.2%) used to take NSAIDs for ten or more days per 
month, with a significant difference between depressed 
(32.9%) and not depressed (19.3%) patients (p = 0.010).
There were no differences between the two groups in 
terms of cDMARDs and biologics’ use. Out of the 70 
depressed patients, 11 (15.7%) were under antidepres-
sant treatment given a personal history of depression. 
On the other hand, a significantly lower proportion of 
non-depressed patients has had a previous diagnosis 
of depression and were taking anti-depressant drugs 
at the moment of assessment (4.5%, p < 0.001). Finally, 
depressed patients were found to take a higher number 
of drugs, i.e. anti-rheumatic drugs plus psychotropic 
therapy (6.4 versus 5.0, p < 0.001).
The association between depression and RA activity 
and disability
Depressed and not depressed patients were compared 
on RA activity and disability (Table  5) by means of 
Table 1 Socio-demographic characteristics of RA patients and their association with depression (n = 490)
Low education: primary/secondary school
Socio‑demographics Total sample (n = 490) Depression according to HADS‑D (cut‑off ≥ 11) p‑value (Chi‑
square or t 
test)Not depressed 
(n = 420)
Depressed (n = 70)
Age (years), mean (sd) 59.5 (12.2) 59.2 (12.1) 61.5 (12.9) 0.141
Female, n (%) 392 (80.0%) 326 (77.6%) 66 (94.3%) 0.001
Marital status, n (%)
Unmarried 57 (11.6%) 48 (11.5%) 9 (12.9%) 0.190
Married 355 (72.4%) 311 (74.0%) 44 (62.8%)
Widowed 38 (7.8%) 30 (7.1%) 8 (11.4%)
Divorced 40 (8.2%) 31 (7.4%) 9 (12.9%)
With children, n (%) 395 (80.6%) 339 (80.7%) 56 (80.0%) 0.889
Low education, n (%) 299 (61.0%) 253 (60.2%) 46 (65.7%) 0.428
Occupation, n (%)
Employed 192 (39.2%) 173 (41.2%) 19 (27.1%) 0.034
Unemployed 298 (60.8%) 247 (58.8%) 51 (72.9%)
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DAS28-CRP, SDAI, CDAI and HAQ scores and their cat-
egories of activity/disability (remission, low, moderate, 
high).
Depressed patients scored significantly higher on all 
RA activity and disability scores. Moreover, by consider-
ing the categories of DAS28-CRP, SDAI and CDAI, the 
percentage of depressed patients increases from remis-
sion to moderate disease activity group, where it reaches 
its maximum, while decreases in high disease activ-
ity group. On the contrary, the trend between depres-
sion and disability shows that depression became more 
frequent in subjects with severe and very severe disability 
accordingly to HAQ scores (p = 0.001).
A series of univariable linear regression models with 
HADS-D score as the dependent variable and each of the 
variables pertaining to conceptual blocks (demographics, 
RA-related variables, RA therapy, psychotropic therapy, 
disease activity and disability indices) as the independent 
one was estimated. Those variables which resulted asso-
ciated at p < 0.10 with the HADS-D score were entered 
into multivariable linear regression models, beginning 
from demographics and adding variables from the other 
Table 2 Clinical characteristics and their association with depression (n = 490)
RF rheumatoid factor; ACPA anti-citrullinated protein antibodies; BMI Body Mass Index, TJC tender joint count; SJC swollen joint count; PhGA physician global 
assessment; PGA patient global assessment; VAS visual analogue scale; ESR erythrocyte sedimentation rate; CRP C-reactive protein
Clinical characteristics Total sample (n = 490) Depression according to HADS‑D (cut‑
off ≥ 11)
p‑value (Chi‑




Depressed (n = 70)
Positive personal history for depression, n (%) 106 (21.6%) 76 (18.1%) 30 (42.8%)  < 0.001
RF and/or ACPA positive, n (%) 292 (59.6%) 246 (58.6%) 46 (65.7%) 0.294
BMI (kg/m2), mean (sd) 25.7 (4.8) 25.7 (4.8) 26.0 (5.1) 0.606
Smoker, n (%) 64 (13.1%) 57 (13.6%) 7 (10.0%) 0.565
Positive family history for rheumatologic disease, n (%) 127 (25.9%) 104 (24.8%) 23 (32.8%) 0.184
Erosions, n (%) 212 (43.3%) 179 (42.6%) 33 (47.1%) 0.516
Disease duration (years), mean (sd) 12.5 (9.6) 12.5 (9.6) 12.4 (9.5) 0.931
TJC 28, mean (sd) 2.1 (3.5) 2.0 (3.5) 2.6 (3.9) 0.197
SJC 28, mean (sd) 1.1 (2.2) 1.1 (2.3) 1.2 (2.1) 0.647
TJC 68, mean (sd) 2.6 (4.0) 2.4 (3.8) 3.7 (4.9) 0.011
SJC 66, mean (sd) 1.4 (2.7) 1.4 (2.7) 1.7 (2.4) 0.324
PhGA, mean (sd) 4.4 (2.7) 4.2 (2.7) 5.5 (2.5)  < 0.001
PGA, mean (sd) 5.3 (2.4) 5.1 (2.4) 6.6 (2.2)  < 0.001
VAS pain, mean (sd) 5.0 (2.7) 4.8 (2.7) 6.3 (2.2)  < 0.001
ESR, mean (sd) 19.9 (16.6) 19.6 (16.6) 21.9 (16.2) 0.276
CRP, mean (sd) 5.6 (8.8) 5.8 (9.3) 4.2 (4.3) 0.179
Vitamin D, mean (sd) 68.8 (28.3) 69.0 (28.1) 68.1 (30.0) 0.806
Haemoglobin, mean (sd) 13.4 (1.3) 13.4 (1.3) 13.2 (1.3) 0.105
Table 3 Presence of comorbidities and their association with depression (n = 490)
Comorbidities Total sample (n = 490) Depression according to HADS‑D (cut‑off ≥ 11) p‑value (Chi‑
square or t 
test)Not depressed(n = 420) Depressed (n = 70)
Comorbidities, n (%) 445 (90.8%) 379 (90.2%) 66 (94.3%) 0.373
Cardiovascular 275 (56.1%) 231 (55.0%) 44 (62.9%) 0.243
Endocrinological 127 (25.9%) 105 (25.0%) 22 (31.4%) 0.302
Neoplastic 58 (11.8%) 49 (11.7%) 9 (12.9%) 0.841
Pulmonary 43 (8.8%) 36 (8.6%) 7 (10.0%) 0.651
Neurological 9 (1.8%) 8 (1.9%) 1 (1.4%) 0.999
Gastroenterological 144 (29.4%) 117 (27.9%) 27 (38.6%) 0.088
Rheumatological 218 (44.5%) 177 (42.1%) 41 (58.6%) 0.013
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conceptual blocks (Table 6). Males (model 1) have lower 
levels of depression than females (variance explained 
3.3%); addition of RA-related variables (model 2) raised 
the variance explained up to 10.7%, with PGA score 
significantly associated with higher depression levels. 
Corticosteroids and NSAIDs (model 3) were not associ-
ated with depression score, while the use of antidepres-
sants and the total number of assumed drugs (model 4) 
increased the variance by 2.2%, with both variables being 
significantly associated with higher depression levels. 
Finally, when disease activity and disability indices (SDAI 
and HAQ, respectively) were added (model 5), the model 
explained 14.5% of the variance, with higher HAQ being 
associated with higher depression score. At this step, 
however, the total number of assumed drugs was no 
longer statistically significant.
Discussion
This study evaluates the prevalence of depression and 
its clinical correlates in terms of disease activity and 
disability in a large sample of patients affected by RA. 
We found a prevalence of depression equal to 14.3% 
(95% CI: 11–17%), that is almost three times higher 
than the prevalence in the general population [15]. 
Depression should therefore be considered such as one 
of the commonest comorbidities of RA and it should 
always be evaluated with screening tests, and treated 
whether necessary, to improve clinical outcomes [16]. 
We also found that depressed patients had higher dis-
ease activity and increased disability indices (SDAI and 
HAQ, respectively). This result underlines the impor-
tance of distinguishing between an increased illness 
activity and an altered disease perception secondary to 
depression.
Previous studies showed great variability in the prev-
alence of depression in patients suffering from RA, 
reaching up to 34–48% [10, 12]. This variability may be 
explained by the different instruments and heterogeneity 
in criteria used to diagnose depression [17]. To avoid an 
overestimation of depression, we decided to use HADS-
D with a cut-off of 11, allowing to identify with greater 
specificity depressed subjects, since it excludes ele-
ments that may reflect physical rather than psychologi-
cal problems. Specifically, the HADS-D does not contain 
questions that investigate quality of sleep, fatigue and 
appetite, symptoms that are common in both depression 
and RA, as it happens in other questionnaires as Hamil-
ton Rating Scale for Depression (HAM-D) [18]. Regard-
ing the choice of the cut off for the HADS, a previous 
study [19] used a cut-off ≥ 8, thus including patients with 
borderline depression leading to a risk to overestimate 
the prevalence of depression. A systematic review [13] 
has identified 30 studies in RA patients in which HADS-
D with a cut-off ≥ 11 was used; an average prevalence of 
depression of 14.8% emerged, which is very close to our 
result.
Regarding the socio-demographic correlates of depres-
sion, we found a significantly higher prevalence of 
depression among female patients (16.8%) compared to 
males (4.1%), in line with previous studies [14, 20, 21]. 
This evidence may be explained by the higher prevalence 
of depression in the general population among women 
[15]. In addition, women tend to undergo more fre-
quently medical treatment, thus increasing the likelihood 
Table 4 Association between anti-rheumatic and psychotropic therapy and depression (n = 490)
cDMARDS: conventional disease-modifying antirheumatic drugs; anti-TNFα: anti-tumor necrosis factors drugs; Total number of drugs: anti-rheumatic drugs plus 
psychotropic therapy
Therapy Total sample (n = 490) Depression according to HADS‑D (cut‑off ≥ 11) p‑value (Chi‑
square or t 
test)Not depressed 
(n = 420)
Depressed (n = 70)
RA therapy
Corticosteroids, n (%) 242 (49.4%) 200 (47.6%) 42 (60.0%) 0.050
NSAIDs (> 10 per month), n (%) 104 (21.2%) 81 (19.3%) 23 (32.9%) 0.010
Vitamin D, n (%) 388 (79.2%) 328 (78.1%) 60 (85.7%) 0.146
Anti-rheumatic drugs
Only cDMARDS, n (%) 199 (40.6%) 170 (40.5%) 29 (41.4%) 0.937
Only anti-TNFα, n (%) 67 (13.7%) 57 (13.6%) 10 (14.3%)
cDMARDS plus anti-TNFα, n (%) 105 (21.4%) 92 (21.9%) 13 (18.6%)
No cDMARDS, no anti-TNFα, n (%) 119 (24.3%) 101 (24.0%) 18 (25.7%)
Psychotropic therapy
Antidepressants, n (%) 30 (35.9%) 19 (4.5%) 11 (15.7%)  < 0.001
Total number of drugs, mean (sd) 5.2 (2.5) 5.0 (2.4) 6.4 (2.8)  < 0.001
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of detecting depression [22]. Furthermore, men tend not 
to complain about their psychological disturbances; on 
the contrary women express themselves more emotion-
ally, obtaining higher scores in questionnaires [23]. In 
our cohort, the percentage of depressed patients is sig-
nificantly higher in those without an occupation (17.1%) 
than in workers (9.9%). Our results are in line with previ-
ous studies [26], suggesting that the employment status 
is protective against the development of depression in 
RA. An association between lower income and depres-
sion has also been detected [26]: less economic resources 
may reduce attention and spending for health. On the 
contrary, other studies reported a positive correlation 
between employment and depressive symptoms [24]. We 
have not distinguished retired from unemployed sub-
jects, therefore, at least half of this group is composed by 
old retired people (i.e. unemployed and aged ≥ 65 years), 
who could have negative feelings of worthlessness, fear 
of the future and sense of isolation, which are psycho-
logical feelings leading to the development of depressive 
symptoms [27]. Conversely, RA itself, causing disability, 
makes more difficult to find or keep a job, especially if it 
is a manual one.
On the other hand, 30 patients with a previous diag-
nosis of depression were still depressed at the time 
of the assessment. Out of them, 11 were depressed 
although under antidepressants. The remaining 19 
depressed subjects were not diagnosed or treated 
despite a previous history of depression. A positive 
history for depression should be considered a risk fac-
tor for the persistence or recurrence of depression in 
RA. Moreover, we found that a considerable portion of 
patients (n = 40) with undetected depression had a neg-
ative history of depression. Thus, this under-recognized 
Table 5 Association between RA activity/disability and depression (n = 490)
DAS28 28-joint Disease Activity Score; SDAI Simplified Disease Activity Index; CDAI Clinical Disease Activity Index; HAQ Health Assessment Questionnaires
DAS28-CRP: remission if ≤ 2.19, low if between 2.19 and 2.60, moderate if between 2.60 and 4.07, high if > 4.07
SDAI: remission if ≤ 3.3, low if between 3.3 and 11, moderate if between 11 and 26, high if > 26
CDAI: remission if ≤ 2.8, low if between 2.8 and 10, moderate if between 10 and 22, high if > 22
HAQ: mild disability if ≤ 0.1, moderate disability if between 0.1 and 1, severe disability if between 1 and 2, very severe disability if > 2
Disease activity and disability 
indices
Total sample (n = 490) Depression according to HADS‑D (cut‑off ≥ 11) p‑value (Chi‑
square or t 
test)Not depressed 
(n = 420)
Depressed (n = 70)
DAS28-CRP, mean (sd) 2.9 (1.1) 2.8 (1.1) 3.2 (0.9) 0.007
DAS28-CRP, n (%)
Remission 231 (47.1%) 209 (49.7%) 22 (31.4%) 0.008
Low 82 (16.7%) 71 (16.9%) 11 (15.8%)
Moderate 160 (32.7%) 125 (29.8%) 35 (50.0%)
High 17 (3.5%) 15 (3.6%) 2 (2.8%)
SDAI, mean (sd) 13.4 (8.2) 12.9 (8.2) 16.3 (7.5) 0.001
SDAI, n (%)
Remission 34 (6.9%) 32 (7.6%) 2 (2.8%) 0.001
Low 176 (35.9%) 163 (38.8%) 13 (18.6%)
Moderate 243 (49.6%) 193 (46.0%) 50 (71.4%)
High 37 (7.6%) 32 (7.6%) 5 (7.1%)
CDAI, mean (sd) 12.9 (8.0) 12.3 (8.0) 15.9 (7.4) 0.001
CDAI, n (%)
Remission 32 (6.5%) 30 (7.1%) 2 (2.8%) 0.001
Low 184 (37.6%) 171 (40.8%) 13 (18.6%)
Moderate 223 (45.5%) 177 (42.1%) 46 (65.7%)
High 51 (10.4%) 42 (10.0%) 9 (12.9%)
HAQ, mean (sd) 0.8 (0.7) 0.7 (0.7) 1.2 (0.7)  < 0.001
HAQ, n (%)
Mild 133 (27.1%) 125 (29.8%) 8 (11.4%)  < 0.001
Moderate 220 (44.9%) 193 (46.0%) 27 (38.6%)
Severe 109 (22.2%) 84 (20.0%) 25 (35.7%)
Very severe 28 (5.7%) 18 (4.2%) 10 (14.3%)
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depression should be addressed with an appropriate 
screening and treatment, keeping in mind that even 
among patients who were under antidepressants, 34.1% 
were still depressed according to HADS-D, suggesting 
that in almost one third of cases those drugs are inef-
fective or maybe at inadequate dosage. These patients 
should be evaluated by a psychiatrist to optimize their 
therapy and followed up closely by the rheumatologist.
Considering the variables used to determine indices 
of disease activity, in our study there is a significant rela-
tionship between depression and TJC, PGA, PhGA and 
VAS, while no association was found between depression 
and disease duration, sieropositivity, erosions, markers of 
inflammation, or swollen joints. Our data further support 
the association between depression and higher pain per-
ception that may affect mainly subjective measurements, 
such as tender joints count, PGA and VAS, as reported 
[25, 26]. Notably, it has been calculated that each extra 
point of depression measured with HADS results in an 
increase of 0.59 in TJC and 2.07 in the PGA score [28]. 
Even if clinical measures based on patients’ reports could 
have important limitations, since they can reflect the 
subjective perception of illness, influenced by many fac-
tors (beliefs, culture, mood), some studies have suggested 
that those measures are better in terms of prediction of 
long-term outcomes, compared to objective parameters 
[29]. Indeed, we observed that objective measurements 
of disease activity (disease duration, ESR, CRP and 
SJC) were not associated with depressive symptoms, as 
reported in other studies [7, 18, 27, 30, 31], but in con-
trast with other ones [12, 17], in which objective scores 
affected mood.
Secondly, we found a significant association between 
RA disease activity and depression and between dis-
ability and depression, assessed through DAS28, SDAI, 
CDAI and HAQ, respectively. These findings were in 
line with previous studies [7, 12, 20]. Patients who 
experience a more active form of RA, with greater 
pain and inflammation, are at higher risk of developing 
depressive disorders. On the other hand, the presence 
of depression in individuals with a chronic disease 
such as RA may increase inflammation and reduce the 
pain threshold, making the disease more active and 
less prone to remission, compared to patients without 
mental disorders [19–21]. Our results underline that 
HAQ is the index that best correlates with depression, 
suggesting that physical disability deeply influence 
mental wellbeing. When we correlated depression 
with DAS28, CDAI and SDAI indices/scores we 
found, against our expectations, a greater prevalence 
of depressive disorders among patients with moder-
ate disease activity compared to high disease activity. 
A possible explanation could be that patients with a 
very active disease are more frequently examined by 
Table 6 Multivariable hierarchical linear regression models with HADS-D score as dependent variable (n = 490)
Independent variables Dependent variable: HADS‑D score
Beta coefficients (p‑value)
Model 1 Model 2 Model 3 Model 4 Model 5
Socio-demographics
Being male  − 1.85 (< 0.001)  − 1.42 (0.001)  − 1.41 (0.001)  − 1.41 (0.001)  − 1.18 (0.007)
RA-related variables
PhGA 0.42 (< 0.001) 0.40 (< 0.001) 0.35 (< 0.001) 0.29 (0.002)
PGA 0.06 (0.387) 0.05 (0.488) 0.04 (0.582) 0.05 (0.587)
RA therapy
Corticosteroids 0.21 (0.547)  − 0.16 (0.657)  − 0.32 (0.383)
NSAIDs (> 10 per month) 0.55 (0.196) 0.48 (0.254) 0.37 (0.382)
Antidepressants 1.96 (0.007) 2.06 (0.004)
Total number of drugs 0.16 (0.035) 0.10 (0.180)
Disease activity and disability indices
SDAI  − 0.03 (0.422)
HAQ 0.97 (0.002)
Goodness of fit indices
Adj R-squared % 3.3% 10.7% 10.7% 12.9% 14.5%
AIC 2723.9 2686.9 2688.9 2678.3 2671.4
BIC 2732.3 2703.7 2714.1 2711.9 2713.4
LR Chi2 – 41.0 1.9 14.6 10.9
p > Chi2 –  < 0.001 0.379  < 0.001 0.004
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a rheumatologist, accordingly to the treat-to-target 
management [32], and this carefulness may poten-
tially reduce depression. Therefore, moderate disease 
activity could be the category at the highest risk of 
developing depression, pointing to the importance of 
screening and monitoring depression in these patients.
The hypothesis that depressive symptoms in patients 
with RA may worsen pain and lead to greater assump-
tion of analgesics is further confirmed by our evi-
dence that patients treated with NSAIDs had higher 
prevalence of depression. It is worth mentioning that 
NSAIDs use is usually self-prescribed, linked to the 
patient’s perception of their health status rather than 
being a treatment prescribed by the physician on the 
basis of objective measures. In our study, we found 
no significant association between the use of specific 
anti-rheumatic drugs and depressive disorders. On 
the other hand, one should keep in mind that it is also 
possible that patients with a more active RA may have 
an increased risk of depression [8], so the relationship 
between RA and depression could be bidirectional.
Depressive symptoms are also associated with phy-
sician perception of disease severity and may influ-
ence the way patients communicate pain and affecting 
clinician’s empathy. Depressive symptoms could also 
overlap with some symptoms of RA, simulating a 
more active and severe arthritis. Furthermore, depres-
sion may create resistance or non-adherence to treat-
ment [33] and this may require a greater therapeutic 
and patient-management effort.
This paper has several strengths. To our best 
knowledge, this is the first large study performed in 
Italy analyzing data from a large sample of patients 
(N = 490) affected by RA. We recruited all subjects 
within the routine clinical practice, rather than a 
sample recruited with strict selection criteria, dur-
ing a whole year in order to increment the generaliz-
ability of our results. We used a set of standardized 
questionnaires, covering a broad number of potential 
correlates of depression in RA, with special attention 
to disease activities and disability. Finally, this study 
arises from a strict collaboration between rheuma-
tologist and psychiatrist leading to a multidisciplinary 
approach to such a relevant RA comorbidity, in both 
design and analysis of this paper.
The main limitation is the cross-sectional design of 
the study that cannot allow us to draw causal infer-
ences on the relationship between depression and RA. 
Moreover, although we used the HADS, which is a 
well-validated and reliable screening tool, the diagno-
sis of depression was not confirmed by a psychiatrist.
Conclusions
In conclusion, our study shows that depression is com-
mon in RA and can lead to an alteration in the per-
ception of the disease since the presence of depression 
is associated with higher disease activity, pain percep-
tion, physical disability. This suggests the importance 
for the rheumatologist to screen and monitor depres-
sion in patients affected by RA in order to treat them 
appropriately. In addition, recognizing and treating 
depression may increase treatment adherence, further 
improving disease control. Although it could sound 
obvious, one should not forget that treating depression 
has significant positive effects on patients’ well-being 
that is one of the main target of the rheumatologist 
work. Finally, since depression is still under-diagnosed 
and almost one third of the patients treated with anti-
depressants does not benefit from the treatment, a 
close collaboration between rheumatologists and psy-
chiatrists is desirable for an adequate diagnosis and 
appropriate therapy.
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